tiprankstipranks
Trending News
More News >

Abeona Therapeutics enters agreement to sell PRV for $155M

Abeona Therapeutics (ABEO) entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $155 million upon the closing of the transaction. Abeona was awarded the PRV following the U.S. Food and Drug Administration approval of ZEVASKYN on April 28, 2025. The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue